NUVL · NASDAQ · Biotechnology

Nuvalent (NUVL)

Developer of selective kinase inhibitors targeting ROS1 and ALK resistance in lung cancer.

$123.96
0.00 (0.00%)
Delisted · Jul 16, 2026